Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 173

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype

Jain, Apurva, Borad, Mitesh J., Kelley, Robin Kate, Wang, Ying, Abdel-Wahab, Reham, Meric-Bernstam, Funda, Baggerly, Keith A., Kaseb, Ahmed Omar, Al-shamsi, Humaid O., Ahn, Daniel H., DeLeon, Thomas, Bocobo, Andrea Grace, Bekaii-Saab, Tanios, Shroff, Rachna T., Javle, Milind · 2018 · JCO Precision Oncology

Abstract

Purpose: FGFR genetic aberrations (GAs) occur in an estimated 10% to 16% of intrahepatic cholangiocarcinomas (CCAs). The natural history of CCA with FGFR GAs, the prognostic role of coexisting GAs, and the outcome with FGFR-targeted inhibitors are unknown. Patients and Methods: Patients with CCA with FGFR GAs were identified using next-generation sequencing or fluorescence in situ hybridization from four tertiary cancer centers and compared with FGFR wild-type counterparts. Data reviewed included demographic, treatment, overall survival (OS), and GA data. Fisher’s exact test, Kaplan-Meier plots, and log-rank tests were used for statistical analysis. Results: Three hundred seventy-seven patients with CCA were identified, and 95 had FGFR GAs. FGFR2 GA was most common (n = 74, with 63 fusions) and seen in intrahepatic CCA. In patients with CCA, FGFR GAs occurred more frequently in younger patients (≤ 40 years; 20%) compared with older patients (> 40 years; 6.7%; P < .001), presented at an earlier stage (TNM stage I/II v III/IV: 35.8% v 22%, respectively; P = .001), and were associated with a longer OS compared with patients without FGFR GAs (37 v 20 months, respectively; P < .001). This difference remained significant after excluding 36 patients treated with FGFR inhibitors. There was no OS difference ( P = .60) between CCA with FGFR2 fusions (n = 63) versus other FGFR GAs (n = 29). Patients with FGFR GAs had a better OS with FGFR-targeted therapy compared with standard treatment ( P = .01). BAP1 mutation was the most common coexisting mutation without prognostic impact, whereas TP53 ( P = .04) and CDKN2A/B ( P = .04) were correlated with a shorter OS. Conclusion: CCA with FGFR GAs represents a unique subtype occurring in younger patients with an indolent disease course. FGFR-targeted therapy may have a positive impact on OS in this subgroup.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/po.17.00080

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 173

Metadata

Authors
Jain, A., Borad, M. J., Kelley, R. K., Wang, Y., Abdel-Wahab, R., Meric-Bernstam, F., Baggerly, K. A., Kaseb, A. O., Al-shamsi, H. O., Ahn, D. H., DeLeon, T., Bocobo, A. G., Bekaii-Saab, T., Shroff, R. T., & Javle, M.
Venue
JCO Precision Oncology
Published
2018-11
Volume
2
Issue
2
Pages
1-12
ISSN
2473-4284 (ISSN-L)
OpenAlex
W2782564608
Cited by
173
References
2
FWCI
13.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. https://app.cochat.ai/papers/10.1200/po.17.00080
The paper
Jain, A., Borad, M. J., Kelley, R. K., Wang, Y., Abdel-Wahab, R., Meric-Bernstam, F., Baggerly, K. A., Kaseb, A. O., Al-shamsi, H. O., Ahn, D. H., DeLeon, T., Bocobo, A. G., Bekaii-Saab, T., Shroff, R. T., & Javle, M. (2018). Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology. https://doi.org/10.1200/po.17.00080

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.